- Short report
- Open Access
Seroprevalence of human respiratory syncytial virus and human metapneumovirus in healthy population analyzed by recombinant fusion protein-based enzyme linked immunosorbent assay
Virology Journalvolume 9, Article number: 130 (2012)
Human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV) are two of the most frequent respiratory pathogens that circulate worldwide. Infection with either virus can lead to hospitalization of young children, immunocompromised people and the elderly.
A better understanding of the epidemiological aspects, such as prevalence of these viruses in the population will be of significant importance to the scientific community. The aim of this study was to gain some detailed knowledge on the humoral immune response to both viruses in different populations of individuals.
The fusion protein (F) of hRSV and hMPV was expressed in the baculovirus and Escherichia coli systems, respectively, and used as antigen in two independent enzyme-linked immunosorbent assays (ELISAs) for detection of specific antibodies in human sera. The seroprevalence of each virus in a large cohort of individuals with ages ranging from 0 to 89 years old was determined. Although the general distribution of the antibody response to each virus in the different age group was similar, the prevalence of hRSV appeared to be higher than that of hMPV in most of them. The group of children with ages between 0 and 2 showed the highest seronegative rates. After this age, an increase in the antibody response was observed, most likely as the result of new infections or even due to reinfections.
The use of these specific F-ELISAs in seroepidemiological studies might be helpful for a better understanding of the human antibody response to these viruses.
Human respiratory syncytial virus (hRSV) is the leading cause of hospitalization for respiratory tract infections in children [1, 2]. More recently, human metapneumovirus (hMPV), a Pneumovirus belonging also to Paramyxoviridae family, has been isolated from children hospitalized with acute respiratory infections in The Netherlands and since, the virus has been reported worldwide [3–5]. Symptoms associated with hMPV infection are very similar to those resulting from hRSV infection, ranging from common cold to severe lower respiratory tract infections, including bronchiolitis and pneumonia. No effective vaccine is currently available towards either hRSV or hMPV, and reinfections occur throughout life [6–8].
The aim of this study was to analyze and compare the specific antibody response in human serum against hRSV and hMPV in a large cohort of individuals with ages ranging from 0 to 89 years old. The fusion protein (F) of both viruses appears as the most suitable candidate for this type of analysis since it is the most immunogenic antigen of the virion and highly conserved among different strains [9–11] . For that purpose, the F protein of hRSV and hMPV was expressed in the baculovirus and Escherichia coli (E. coli) system, respectively, and used as antigen in two independent ELISAs.
Materials and methods
Serum samples from 1811 healthy patients were randomly collected from archives of the Institute of Virology of the University Hospital Bonn.
An ethical vote from the University of Bonn Ethical Committee permitted us to use the samples retrospectively. No written informed consent was necessary as no personal data were used and as it was an epidemiological study. All procedures were carried out in accordance to the Helsinki declaration in its present form.
Cloning and expression of the fusion protein of hRSV and hMPV
A soluble version of the F protein of hRSV, Long strain (Fs, 24-524aa) was expressed in the baculovirus system as previously described .
The recombinant F protein of hMPV was prepared using the E. coli system. The pCR4-TOPO vector containing the F protein gene of hMPV (isolate NL/1/99) was used to amplify a soluble version of the F protein gene (Fs, nt 601–1413) by PCR with primers F + (5’-ATG CTAAATGTTGTGCGGCAGTTT-3’) and F- (5’-TTA TCCTTTTTCTGCACTGTTTAG-3’). The PCR product was further cloned in the pDEST™17 expression vector (Invitrogen) that contains an N-terminal 6xHis tag. The recombinant F protein was expressed by transformation of BL21 cells. Overnight (ON) cultures of transformed bacteria were inoculated in Luria Broth medium supplemented with 1 % ampicillin. Cultures were grown to exponential phase prior to induction with arabinose 20 % for 3 hours. The F protein was partially purified from inclusion bodies by solubilization procedures using the following buffer: 50 mM Tris–HCl, 50 mM NaCl, 0.5 mM EDTA, 5 mM TCEP, 5 % glycerol and 30 % N-Lauroylsarcosine, pH 8.
Enzyme-linked immunosorbent assay
Detection of serum antibodies against the F protein of hRSV by ELISA has been previously published .
For detection of antibodies against hMPV, the recombinant F protein expressed in the E. coli system was used as antigen to coat 96-well microtitre plates (0,2 μg/well). After ON incubation at 4 °C, the wells were blocked and a 1/500 dilution of human serum in 0.05 % Tween in Phosphate-Buffered Saline (PBS) was incubated for 1 hour at RT. Bound antibodies were detected by incubation with peroxidase-labelled anti-human IgG and subsequent addition of the substrate tetramethylbenzidine (TMB-MAX, Neogen Corporation). The cut-off value of the assay was defined by adding 2 standard deviations (SD) to the mean optical density (OD) value of 10 negative samples . These samples were previously established as negative by comparison with negative controls tested by immunofluorescence and kindly provided by Dr. Catherine Manoha (University Hospital Dijon).
Expression of the fusion protein of hRSV and hMPV
The F protein of hRSV and hMPV were expressed using the baculovirus and E. coli expression systems, respectively. A specific pool of positive human sera against the F protein of each virus was used to confirm the antigenicity of the recombinant proteins by Western blot (Figure 1A and 1B). Incubation of the nitrocellulose membranes with each pool of sera revealed a band corresponding to expected molecular mass of each recombinant protein.
Analysis of the antibody response towards hRSV and hMPV
In order to investigate the incidence of hRSV and hMPV in the population, a set of 1811 serum samples from patients with ages ranging from 0 to 89 years of age, was included in the present study. The specific antibody response of each serum to the F protein of both viruses was measured by indirect ELISA. Each serum sample was tested at a single dilution for screening purposes. The optimal dilution was previously determined on the basis of OD yielded from the ELISA with twofold serial dilutions of control serum samples against positive and negative antigens prepared in the same conditions.
Figure 2 shows the seropositivity against each virus in the different age groups. The high values of the SD in each age group were due to a wide range of positivity defined by the cutoff values (0.378 and 0.357 for hRSV and hMPV, respectively). Thus, samples with OD equal or higher than the cut-off, independently of the magnitude of the OD, were considered positive and sera with readings lower than the cut-off were considered negative. The percentages of seropositive and seronegative samples in each age group of patients are shown in Table 1. Although the general distribution in the different age groups for both viruses was similar, the prevalence of hRSV was higher than that of hMPV in the majority of the groups.
Patients with ages between 0 and 2 years old, showed the highest percentage of seronegative samples for the two viruses (63.7 % for hRSV and 47.5 % for hMPV). Then, an increase of the seropositive rates was observed in the cohort of individuals from 2 to 9 years old, with percentages of 71.4 % and 85.7 % for hRSV and hMPV, respectively. The group of patients with ages between 10 and 69 years old showed an average of seropositivity of 94.8 % for hRSV and 86.6 % for hMPV. Finally, a minor drop in the seropositivity was observed in the elderly population between 70–89 years when measuring the antibody response to hMPV. In the case of hRSV, the population between 70 to 79 years old showed similar seropositive rates to the ones of younger groups, followed by a moderate decrease in the oldest group of patients with ages between 80–89 years old.
Although several studies have used single recombinant viral proteins as ELISA antigens for measurement of antibody response to hRSV and hMPV [14, 15], this is the first time that the same set of sera comprising a wide range of ages is tested to compare the specific antibody response against the F protein of the two viruses. To do so, the fusion protein of each virus was partially purified and used in an ELISA to detect the presence of specific antibodies in a large cohort of individuals with ages ranging from 0 to 89 years. Since the F protein of each virus was expressed in different systems and bearing in mind that post-transductional modifications do not occur in bacteria and the ones in insect cells differ from the ones in mammalian cells, the antigenicity of both proteins was first tested by Western Blot analysis with a positive pool of human sera. A band corresponding with the expected molecular size of each recombinant fusion protein was confirmed (Figure 1A and 1B).
By the age of 2 to 5 years most children have been infected at least once with both hRSV and hMPV [1, 4]. In the present report, the youngest group of individuals with ages between 0 and 2 years showed the lowest antibody response to either virus. A broad range of ages are included in this group with a high percentage of children younger than 1 year old. The immaturity of the immune system of these infants could explain the low antibody level. Furthermore, the level of antibodies in this group could be even lower, since some of these sera samples may contain maternally derived antibodies, which may not represent true seropositivity due to infection. A rise in the antibody response against both viruses in the groups of individuals with ages between 2–69 years old was detected, probably as result of re-infections. Finally, the oldest group of patients from 70 to 89 years old, showed a significant antibody response towards both viruses, however they still comprise one of the groups at high risk of infection with elevated rates of morbidity . Previous studies have shown that the percentage of neutralizing antibodies against hRSV in the frail people (> 80 years old) is very low, despite having a considerable level of specific antibodies against the virus. This poor neutralizing antibody response is probably one of the causes for the susceptibility of this group of individuals to develop severe disease after infection with hRSV . A recent study has analyzed the neutralizing ability to inhibit hMPV replication using the same set of sera used in the present work . No correlation between neutralizing ability of a given serum and antibody levels was found. Most strikingly there was an already high neutralizing capacity of the sera of the youngest group of patients although this group had the highest rate of seronegativity. For the 70–79 age group the seropositivity was 57.9 % versus 90 % neutralization. The same was true for the other age groups in which the presence of antibodies does not necessarily mean that there is also a high level of neutralizing antibodies. Although neutralizing ability is commonly associated with the presence of neutralizing antibodies in a serum sample, in the Lusebrink et al. study the authors claim that is not solely the neutralizing antibodies which inhibit hMPV replication but also other neutralizing factors, such us interferon. Taking this into consideration it is not surprising that both studies do not correlate, although the set of sera used for both studies was identical. In concert with the study by Lüsebrink et al. it appears likely that neutralizing antibodies play a minor role in the control of hMPV and hRSV infections in humans, a hypothesis that is supported by the fact that virtually all approaches to develop a potent and long lasting vaccine against both viruses have failed so far.
In the present study the F protein of NL/1/99 strain belonging to the B1 sublineage of hMPV and the F protein of the Long strain of subgroup A of hRSV have been used. Although, as mentioned in the introduction, the variability of the F protein belonging to the different subgroups and sublineages of hRSV and hMPV is low, in the developed ELISAs, some anti-F antibodies could be disregarded and therefore false negative results could be potentially obtained in both cases. However, it is well known that anti-hRSV antibodies directed against the F protein are cross-reactive for strains of both subtypes (A and B) , and studies on hMPV using the F protein as a subunit vaccine have indicated similar antibody reactivity patterns against homologous and heterologous hMPV infections [20, 21].
Finally, as shown in Table 1, most age groups showed that the prevalence of hRSV was higher than that of hMPV, however children with ages from 0 to 9 years old had higher rates of seropositivity to hMPV than to hRSV. Several groups have studied the seroprevalence of hMPV and hRSV in young children, with different results. For instance, in The Netherlands all children have been infected with hMPV by the age of 5 . In Canada, the majority of patients over 16 years old were seropositive for hMPV . In Japan, Ebihara et al found that seropositive rates of hMPV were lower than those of hRSV in all children between 1 month and 5 years and a recent study in China showed that seropositive rates of hMPV in children 6 months to 6 years of age were significatively lower than seropositive rates of hRSV [22, 23]. This variety of results may reflect different infection patterns between the two viruses, but also different seroprevalence patterns between geographical locations.
In summary, the present study shows that the distribution of hRSV and hMPV in the general healthy population in the area of Bonn (Germany) is very similar, with hRSV infections more frequent that those of hMPV in most age groups. This kind of analysis appears to be an appropriate instrument for seroepidemiological studies, although it should be used in combination with neutralization test for a more comprehensive analysis.
Human respiratory syncytial virus
- E. coli:
Enzyme-linked immunosorbent assay
Henderson FW, Collier AM, Clyde WA, Denny FW: Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 1979,300(10):530-534. 10.1056/NEJM197903083001004
Boyce TG, Mellen BG, Mitchel EF, Wright PF, Griffin MR: Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000,137(6):865-870. 10.1067/mpd.2000.110531
Ebihara T, Endo R, Kikuta H, Ishiguro N, Yoshioka M, Ma X, Kobayashi K: Seroprevalence of human metapneumovirus in Japan. J Med Virol 2003,70(2):281-283. 10.1002/jmv.10391
van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, Osterhaus AD: A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001,7(6):719-724. 10.1038/89098
Liu L, Bastien N, Sidaway F, Chan E, Li Y: Seroprevalence of human metapneumovirus (hMPV) in the Canadian province of Saskatchewan analyzed by a recombinant nucleocapsid protein-based enzyme-linked immunosorbent assay. J Med Virol 2007,79(3):308-313. 10.1002/jmv.20799
Ryder AB, Tollefson SJ, Podsiad AB, Johnson JE, Williams JV: Soluble recombinant human metapneumovirus G protein is immunogenic but not protective. Vaccine 2010,28(25):4145-4152. 10.1016/j.vaccine.2010.04.007
Tang RS, Spaete RR, Thompson MW, MacPhail M, Guzzetta JM, Ryan PC, Reisinger K, Chandler P, Hilty M, Walker RE, Gomez MM, Losonsky GA: Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. Vaccine 2008,26(50):6373-6382. 10.1016/j.vaccine.2008.09.018
Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE, Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, Wittek AE, Casey R, Eichelberger M, Thumar B, Randolph VB, Udem SA, Chanock RM, Murphy BR: Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000,182(5):1331-1342. 10.1086/315859
Alansari H, Potgieter LN: Molecular cloning and sequence analysis of the phosphoprotein, nucleocapsid protein, matrix protein and 22 K (M2) protein of the ovine respiratory syncytial virus. J Gen Virol 1994,75(Pt 12):3597-3601.
Stott EJ, Taylor G, Ball LA, Anderson K, Young KK, King AM, Wertz GW: Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J Virol 1987,61(12):3855-3861.
Yang CF, Wang CK, Tollefson SJ, Piyaratna R, Lintao LD, Chu M, Liem A, Mark M, Spaete RR, Crowe JE, Williams JV: Genetic diversity and evolution of human metapneumovirus fusion protein over twenty years. Virol J 2009, 6: 138. 10.1186/1743-422X-6-138
Sastre P, Cusi MG, Manoha C, Schildgen O, Ruiz T, Vela C, Rueda P: Serum antibody response to respiratory syncytial virus F and N proteins in two populations at high risk of infection: children and elderly. J Virol Methods 2010,168(1–2):170-176.
Jacobson RH: Validation of serological assays for diagnosis of infectious diseases. Rev Sci Tech 1998,17(2):469-526.
Buraphacheep W, Britt WJ, Sullender WM: Detection of antibodies to respiratory syncytial virus attachment and nucleocapsid proteins with recombinant baculovirus-expressed antigens. J Clin Microbiol 1997,35(2):354-357.
Leung J, Esper F, Weibel C, Kahn JS: Seroepidemiology of human metapneumovirus (hMPV) on the basis of a novel enzyme-linked immunosorbent assay utilizing hMPV fusion protein expressed in recombinant vesicular stomatitis virus. J Clin Microbiol 2005,43(3):1213-1219. 10.1128/JCM.43.3.1213-1219.2005
Falsey AR, McCann RM, Hall WJ, Tanner MA, Criddle MM, Formica MA, Irvine CS, Kolassa JE, Barker WH, Treanor JJ: Acute respiratory tract infection in daycare centers for older persons. J Am Geriatr Soc 1995,43(1):30-36.
Terrosi C, Di Genova G, Martorelli B, Valentini M, Cusi MG: Humoral immunity to respiratory syncytial virus in young and elderly adults. Epidemiol Infect 2009,137(12):1684-1686. 10.1017/S0950268809002593
Lusebrink J, Wiese C, Thiel A, Tillmann RL, Ditt V, Müller A, Schildgen O, Schildgen V: High seroprevalence of neutralizing capacity against human metapneumovirus in all age groups studied in Bonn, Germany. Clin Vaccine Immunol 2010,17(3):481-484. 10.1128/CVI.00398-09
Hendry RM, Burns JC, Walsh EE, Graham BS, Wright PF, Hemming VG, Rodriguez WJ, Kim HW, Prince GA, McIntosh K, Chanock RM, Murphy BR: Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. J Infect Dis 1988,157(4):640-647. 10.1093/infdis/157.4.640
Herfst S, de Graaf M, Schrauwen EJ, Ulbrandt ND, Barnes AS, Senthil K, Osterhaus AD, Fouchier RA, van den Hoogen BG: Immunization of Syrian golden hamsters with F subunit vaccine of human metapneumovirus induces protection against challenge with homologous or heterologous strains. J Gen Virol 2007,88(Pt 10):2702-2709.
Skiadopoulos MH, Biacchesi S, Buchholz UJ, Riggs JM, Surman SR, Amaro-Carambot E, McAuliffe JM, Elkins WR, St Claire M, Collins PL, Murphy BR: The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J Virol 2004,78(13):6927-6937. 10.1128/JVI.78.13.6927-6937.2004
Ebihara T, Endo R, Kikuta H, Ishiguro N, Ishiko H, Kobayashi K: Comparison of the seroprevalence of human metapneumovirus and human respiratory syncytial virus. J Med Virol 2004,72(2):304-306. 10.1002/jmv.10572
Lu G, Gonzalez R, Guo L, Wu C, Wu J, Vernet G, Paranhos-Baccalà G, Wang J, Hung T: Large-scale seroprevalence analysis of human metapneumovirus and human respiratory syncytial virus infections in Beijing China. Virol J 2011, 8: 62. 10.1186/1743-422X-8-62
We thank Ramona-Liza Tillmann for her technical assistance. This research was supported by EU FP6-2005-LIFESCHEALTH-7 (GRANT 37276 “RespViruses”) and partially by a grant from the Else Kröner-Fresenius Stiftung (Germany).
The authors declare that they have no competing interests.
PS and PR designed the experiments and analyzed the results, TR and PS performed the experiments, VS provided the serum samples and designed experiments, PR, OS and CV contributed in critical discussion of the results, writing of the manuscript and supervised different parts of the study.